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Identification of TROP2 (TACSTD2), an
EpCAM-Like Molecule, as a Specific Marker for
TGF-b1-Dependent Human Epidermal
Langerhans Cells
Gregor Eisenwort1, Jennifer Jurkin1, Nighat Yasmin1, Thomas Bauer1, Bernhard Gesslbauer1 and
Herbert Strobl1
Langerin (CD207) expression is a hallmark of epidermal Langerhans cells (LCs); however, CD207þ cells comprise
several functional subsets. Murine studies showed that epidermal, but not dermal, CD207þ cells require
transforming growth factor-b 1 (TGF-b1) for development, whereas human data are lacking. Using gene
profiling, we found that the surface molecule TROP2 (TACSTD2) is strongly and rapidly induced during TGF-b1-
dependent LC commitment of human CD34þ hematopoietic progenitor cells or monocytes. TROP2 is
conserved between mouse and human, and shares substantial amino-acid identity with EpCAM, a marker for
murine epidermal LCs. To our knowledge, neither TROP2 nor EpCAM expression has been analyzed in human
dendritic cell (DC) subsets. We found that (i) all human epidermal LCs are TROP2þEpCAMþ ; (ii) human
dermis lacks CD207þEpCAM or CD207þTROP2 DCs, i.e., equivalents of murine dermal CD207þ DCs; and
(iii) pulmonary CD207þ cells are TROP2EpCAM. Moreover, although EpCAM was broadly expressed by
pulmonary and intestinal epithelial cells, as well as by bone marrow erythroid progenitor cells, these cells
lacked TROP2. However, although TROP2 is expressed by human LCs as well as by human and murine
keratinocytes, most murine LCs, except of a small subset, lacked TROP2. Therefore, TROP2 is a marker for
human TGF-b1-dependent epidermal LCs.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting cells
(APCs) that can be found in a variety of lymphoid and non-
lymphoid tissues (Merad and Manz, 2009). Although they are a
promising target for vaccine development and tumor immu-
notherapy, their functional spectrum is not fully understood
(Palucka et al., 2011; Ueno et al., 2011). Furthermore, most
functional studies analyzing specific DC subsets are conducted
in mice. In order to translate findings from murine models to the
clinics, a better interspecies correlation of DC subsets is a
prerequisite. Accordingly, human equivalents of murine DC
subsets such as CD8aþ DCs resembling human DNGR1þ DCs
have recently been discovered (Bachem et al., 2010; Crozat
et al., 2010; Jongbloed et al., 2010; Poulin et al., 2010).
Considering increasing evidence for additional DC subsets
identified in mouse (Bar-On et al., 2010; Henri et al., 2010), a
better phenotypic analysis of human DC subsets is necessary.
Langerhans cells (LCs) are the DCs of the epidermis. In
contrast to other DC sub-populations, they have traditionally
been defined by their expression of the C-type Lectin receptor
Langerin (CD207) (Romani et al., 2010). With the recent
discovery of CD207þ , dermal DCs, and the fact that CD207
is also expressed by CD8aþ DCs in lymphoid tissues in mice,
the need for previously unreported specific LC markers
became evident. The epithelial adhesion molecule EpCAM
can be used to study murine skin DC subsets (Borkowski
et al., 1996b). Dermal and epidermal CD207þ DCs can be
discriminated by the expression of EpCAM (Bursch et al.,
2007; Ginhoux et al., 2009; Nagao et al., 2009a). However,
despite these important observations in mice, data in the
human system are still lacking.
In our study we aimed to identify previously unreported
marker molecules for human epidermal LCs. Transforming
growth factor-b 1 (TGF-b1) addition to cultures of monocytic
cells is sufficient to induce an LC phenotype (Strobl et al., 1996).
Therefore, we screened for TGF-b1 response genes during LC
lineage commitment using a genome-wide array approach.
& 2011 The Society for Investigative Dermatology www.jidonline.org 2049
ORIGINAL ARTICLE
Received 29 March 2011; revised 26 April 2011; accepted 28 April 2011;
published online 16 June 2011
1Institute of Immunology, Center of Pathophysiology, Infectiology and
Immunology, Medical University of Vienna, Vienna, Austria
Correspondence: Herbert Strobl, Institute of Immunology, Center of
Pathophysiology, Infectiology and Immunology, Medical University of
Vienna, Lazarettgasse 19/3, 1090 Vienna, Austria.
E-mail: herbert.strobl@meduniwien.ac.at
Abbreviations: DC, dendritic cell; LC, Langerhans cell; moDC, monocyte-
derived dendritic cell; moLC, monocyte-derived Langerhans-like cell;
TGF-b1, transforming growth factor-b 1
We here identified TROP2, an evolutionary highly
conserved molecule, which shows 48% amino-acid identity
to EpCAM (El Sewedy et al., 1998), as a specific marker for
human epidermal LCs.
RESULTS
Identification of TROP2 as a TGF-b1 response gene during
Langerhans cell commitment of CD34þ cells
We recently undertook gene array profiling of purified human
myeloid progenitor cells undergoing TGF-b1-dependent LC
commitment and differentiation (data not shown). In this
screen, serum-free cultures of flow-sorted myeloid-com-
mitted CD34þCD45RAþCD19 cord blood cells were
supplemented with a combination of cytokines that promotes
monocytic cell differentiation. Addition of TGF-b1 re-
directed monocyte to LC differentiation, as previously
described by our group (Strobl et al., 1997; Heinz et al.,
2006). Among the strongest induced genes at 6 and 24 hours
after TGF-b1 stimulation was TACSTD2 (TROP2). Similar to
EpCAM, TROP2 is expressed by epithelial tumor cells; in
addition, flow-sorting experiments demonstrated that TROP2
expression allows to positively identify prostate stem cells
and hepatic oval cells (Goldstein et al., 2008; Okabe et al.,
2009). However, TROP2 expression by cells of the hemato-
poietic system was to our knowledge not described so far.
Although TROP2 was strongly induced in response to TGF-b1
stimulation, EpCAM showed only weak induction (Figure 1a).
Congruent with this, progenitor cells show much higher
induction of TROP2 than EpCAM mRNA levels in TGF-b1-
dependent day 7-generated LCs (Figure 1b). Protein expres-
sion analyses revealed that in vitro-generated CD207þ LCs
are TROP2þEpCAMþ (Figure 1c). Parallel cultures in which
TGF-b1 had been omitted gave rise to monocytic cells and
CD1aþ cells lacking CD207 (Figure 1c lower panel and data
not shown); these cells lacked detectable expression of
TROP2 or EpCAM (Figure 1c, lower gates). LCs may gradually
lose epithelial-associated marker molecules upon migration
from epidermis to lymphoid tissues or during in vitro
maturation, as previously demonstrated for E-cadherin (Jakob
and Udey, 1998; Riedl et al., 2000). Therefore, we analyzed
whether LC activation/maturation is associated with changes
in TROP2 or EpCAM expression. In vitro-generated CD34þ
progenitor cell-derived LCs were cluster purified as demon-
strated previously (Gatti et al., 2000), and subsequently
induced to undergo maturation in response to tumor necrosis
factor-a plus IL-1b stimulation. LC maturation was marked by
strong upregulation of CD83 and CD86; average mean
fluorescence intensities of TROP2 and EpCAM slightly
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Figure 1. TROP2 is induced upon TGF-b1-dependent LC commitment of
CD34þ cells. (a) Bars represent mean upregulation of TROP2 and EpCAM at
6 and 24 hours relative to 0 hours after initiation of Langerhans cells (LC)
cultures±transforming growth factor (TGF)-b1 (n¼6 donors). (b) Real-time
PCR analysis of TROP2 and EpCAM expression after 7 days of LC cultures
(n¼4 donors). (c) Cells were gated after 7 days and were analyzed for TROP2
or EpCAM expression. (d) Day-7 LCs were cluster purified and stimulated with
GM-CSF, tumor necrosis factor-a, and IL-1b for 48 hours or GM-CSF alone.
Empty histograms in c and d represent isotype controls; bars in b and c
represent the mean and SEM of three independent experiments. *Po0.05;
**Po0.01; ***Po0.001. MFI, mean fluorescence intensity; NS, not
significant.
2050 Journal of Investigative Dermatology (2011), Volume 131
G Eisenwort et al.
Identification of TROP2 as LC Marker
increased during maturation (Figure 1d). We conclude that
TROP2 is induced by TGF-b1 during LC commitment/
differentiation of myeloid progenitor cells, and both TROP2
and EpCAM show stable expression during maturation of
in vitro-generated CD207þ LCs.
Erythropoietic cells express EpCAM but not TROP2
In order to evaluate TROP2 and EpCAM as potential
LC-specific marker molecules, we systematically analyzed
their expression among hematopoietic cells. Normal peripheral
blood leukocytes lacked detectable expression of both
markers (Figure 2a). Conversely, a minor subset of bone
marrow cells expressed EpCAM but not TROP2 (Figure 2b).
EpCAM and E-cadherin were previously found to be
expressed by human erythropoietic cells (Lammers et al.,
2002). Congruent with these observations, most gated
EpCAMþ bone marrow cells represented glycophorin-Aþ
erythroid progenitor cells (Figure 2b). As it is known that
erythropoiesis transits through an EpCAMþE-cadherinþ stage
and that TGF-b1 accelerates in vitro erythropoiesis (Zermati
et al., 2000), we analyzed whether TGF-b1 might induce
TROP2 expression in erythropoietic progenitors. Thus,
CD34þ cord blood cells were induced to differentiate to
erythropoietic cells in response to erythropoietin, IL-3, and
stem cell factor in SFM. Parallel cultures were further
supplemented with TGF-b1. FACS analyses confirmed pre-
vious observations (Zermati et al., 2000): In the absence of
TGF-b1, erythroid progenitors first acquired increasing CD71
expression; this was followed by the induction of glycophor-
in-A by CD71hi cells (Figure 2c). TGF-b1 promoted the
transition to glycophorin-Aþ cells (Figure 2c, left panel), with
most cells positive for glycophorin-A and showing reduced
CD71 expression (Figure 2c, lower panel). Although erythroid
cells co-expressed E-cadherin and EpCAM as expected from a
previous study (Lammers et al., 2002), these cells lacked
detectable TROP2 expression (Figure 2c). Moreover, TGF-b1
failed to induce TROP2 expression by erythropoietic cells
(Figure 2c). These data demonstrate that TROP2 is not
expressed by bone marrow erythropoietic cells, even when
stimulated by TGF-b1, whereas erythropoiesis transits
through an EpCAMþE-cadherinþ cell stage.
TROP2 is strongly expressed by moLCs, whereas these
cells lack EpCAM
Previous studies revealed that the addition of TGF-b1 to GM-
CSF plus IL-4-supplemented cultures of human monocytes
induces the generation of DCs showing phenotypic char-
acteristics of LCs (moLCs) (Geissmann et al., 1998). To test
whether moLC differentiation is accompanied by TROP2 and/
or EpCAM expression, CD14þ monocytes were induced to
differentiate to classical monocyte-derived DCs (GM-CSF/IL-
4) or moLCs (GM-CSF/IL-4/TGF-b1). Alternatively, they were
cultured in GM-CSF only to induce macrophage differentia-
tion. moLCs strongly expressed TROP2 but lacked detectable
EpCAM (Figure 3). Additionally, a minor portion of mono-
cyte-derived DCs in the absence of TGF-b1 weakly expressed
TROP2. Furthermore, macrophages were TROP2EpCAM
(Figure 3). Therefore, moLCs generated in the presence of
TGF-b1 strongly express TROP2, but lack detectable EpCAM
expression.
TROP2 is expressed by epidermal Langerhans cells and
keratinocytes in situ
Staining of epidermal-cell suspensions revealed that viable
CD45þHLADRþCD207þ LCs (identified in Figure 4a) are
strongly positive for TROP2 and EpCAM (Figure 4b and c);
CD45HLA-DR keratinocytes (KCs) showed similar bright
TROP2 staining as observed for LCs; however, these cells
showed weaker expression of EpCAM compared with LCs
(Figure 4a–c). In situ immunofluorescence analyses of TROP2
in healthy human breast skin revealed a strong epidermal
staining pattern, thus confirming previous observations (Klein
et al., 1987). Co-staining with CD207 showed that LCs
express TROP2 (Figure 4d). In comparison with TROP2,
EpCAM showed weaker staining of KCs; however, CD207þ
cells co-expressed EpCAM to a similar extent as observed for
TROP2 (Figure 4e). These data demonstrate that LCs in situ
co-express TROP2 and EpCAM.
High levels of TROP2 expression on DCs in dermal
preparations are restricted to migratory LCs
Dermal CD207þ cells were recently identified in mice,
based on the expression of CD207 in the absence of EpCAM.
Whether human equivalents of murine dermal CD207þ cells
exist has, to our knowledge, not been studied. Human dermal
DCs have previously been extensively studied leading to the
delineation of at least three DC subsets (Klechevsky et al.,
2008). These include CD207þCD1ahi cells (Angel et al.,
2006), CD1aint cells, as well as CD1aCD14þ DCs.
Although all three subsets could clearly be defined by flow
cytometry (see gated populations in Figure 5a and data not
shown), high levels of TROP2 and EpCAM expression were
restricted to the small CD207þCD1ahi subset. The CD1aint
subset showed distinctively lower TROP2, and both markers
were absent from the CD1aCD14þ subset (Figure 5a,
histograms and data not shown). Therefore, we demonstrate
here that using a similar staining strategy as described for
mice, human equivalents of murine dermal CD207þ cells
cannot be delineated.
DCs from lung and gut are TROP2/EpCAM
Similar to the epidermis, CD207þ DCs have been described
in several mucosal surfaces that are in contact with the
environment, such as the lung, oral cavity, and vagina
(Hladik et al., 2007; Allam et al., 2010; Van Pottelberge et al.,
2010). Conversely, the intestinal mucosa seems to be
devoid of CD207þ cells (Watanabe et al., 2007). We
screened lung and colon tissue for the presence of
CD207þTROP2þEpCAMþ cells. Although CD207þ DCs
could be detected within the pulmonary interstitial tissue,
these cells lacked TROP2 and EpCAM expression; EpCAM,
however, was expressed by the majority of the CD45 cells
(Figure 5b, histograms). Intestinal lamina propria did not
contain any detectable CD207þ DCs (Figure 5c). The
numerous HLA-DRþ DCs within the lamina propria were
similar to their pulmonary counterparts negative for TROP2
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Figure 2. Lack of TROP2 but not EpCAM expression among erythropoietic cells. (a) FACS analysis of neutrophilic granulocytes and peripheral blood
mononuclear cells (PBMCs) for TROP2 and EpCAM expression. (b) FACS analysis of a bone marrow aspirate for TROP2 and EpCAM expression. Empty
histogram represents isotype control. (c) Hematopoietic progenitor cells were induced to differentiate in vitro from erythroid cells in response to erythropoietin,
stem cell factor, and IL-3; parallel cultures were further supplemented with transforming growth factor (TGF)-b1. FACS analyses of cells after 5 days of culture.
MNCs, mononuclear cells; SSC, side scatter.
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and EpCAM, whereas the intestinal CD45 cells were
EpCAMþ (Figure 5c, histograms).
TROP2 allows the identification of a minor LC subfraction
in mice
Human and murine TROP2 show 79% identical amino-acid
composition (El Sewedy et al., 1998). Although EpCAM
expression within the murine skin has been extensively
studied (Nagao et al., 2009a), to our knowledge, TROP2 has
not been analyzed so far. By examining epidermal ear sheets
of wild-type C57BL/6 mice, we found TROP2 to be expressed
by the majority of KCs, similar to what has been described in
the human system (Klein et al., 1987). However, most LCs
(approximately 90%) lacked TROP2 (Figure 6a). Analyses of
single-cell suspensions confirmed the histological data:
Although KCs were all TROP2þ , the majority of LCs lacked
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CD14, TROP2, and EpCAM on the indicated dendritic cell (DC) subtypes after
5–7 days of culture. (b) Cells were gated as indicated and were analyzed for
TROP2 and EpCAM expression. Empty histograms represent isotype controls.
Bars represent the mean and SEM of three independent experiments.
*Po0.05. GM-CSF, granulocyte macrophage colony-stimulating factor;
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Figure 4. TROP2 and EpCAM expression by LCs and keratinocytes isolated
from human skin and in situ. (a) FACS analysis of human epidermal single-
cell suspensions. The gating strategy to identify LCs and keratinocytes (KC)
is shown. (b) TROP2 and EpCAM expression by LC and KC as gated in a.
Empty histograms represent isotype controls. One representative experiment
of five is shown. (c) Relative mean fluorescence intensity (MFI) of TROP2 and
EpCAM. Cells were analyzed as shown in a and b. Bars represent the mean
and SEM of three independent experiments. (d, e) Tissue immunofluorescence
staining of human breast skin cryosections for TROP2 (d) or EpCAM (e) and
CD207. Nuclei are visualized with DAPI. Data are representative of four
independent experiments. Bars¼ 25mm. SSC, side scatter.
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TROP2 expression. A minor fraction of CD207þ cells were
TROP2þ (i.e., 9.8±0.9%). Furthermore, epidermal gd-T-
cells, known to reside within CD45þMHC-II epidermal cell
fractions, lack TROP2 (Figure 6b and c).
DISCUSSION
Anti-EpCAM stainings recently enabled the identification of a
previously unreported murine DC subset, the so-called
dermal CD207þ DCs. EpCAM expression is restricted to
epidermal LCs; therefore allowing to subdivide dermal
CD207þ cells into migratory epidermal LCs (EpCAMþ ) and
dermal-resident cells (EpCAM). To our knowledge, EpCAM
has not been evaluated as a candidate marker molecule for
the classification of human DC subsets.
Here we show that TROP2 and EpCAM are co-expressed
by epidermal LCs. Moreover, we provide evidence that
human dermis lacks an analogous population to murine
dermal CD207þ cells, and that CD207þ DCs from lung
differ from LCs in that they are mostly TROP2EpCAM;
similarly intestinal DCs were TROP2EpCAM. We further-
more showed that TROP2, but not EpCAM, is strongly
induced during TGF-b1-dependent LC lineage commitment
of monocytopoietic cells. Finally, on the basis of TROP2 and
EpCAM expression, TGF-b1-dependent CD34þ cell-derived
CD1aþCD207þ cells resemble LCs in vivo, therefore
supporting other data that these cells are model cells of LCs.
Among the DC subsets analyzed in this study, only skin
DCs expressed EpCAM and TROP2. These EpCAMþTROP2þ
DCs represent epidermal-resident LCs as well as
dermal-migratory LCs, the latter constituting a minor dermal
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Figure 6. TROP2 expression in the murine epidermis. (a) Tissue
immunofluorescence staining of murine epidermal ear sheet for TROP2 and
major histocompatibility complex-II (MHC-II). Nuclei are visualized with
DAPI. The arrowhead indicates a TROP2þMHC-IIþ cell. Bars¼ 25 mm.
(b) FACS analysis of a murine epidermal single-cell suspension. Gates were
set to obtain cell fractions enriched for keratinocytes (KC, CD45), gd-T-cells
(TC, CD45þMHC-II), and LC (CD45þMHC-IIþ ). (c) TROP2 expression by
sub-populations gated in b; empty histograms represent isotype controls; data
are representative of 10 experiments. KC, keratinocytes; LC, Langerhans cells.
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DC subset characterized by high expression levels of
CD207 (Angel et al., 2006). Although dermal-resident
CD1aþCD207 DCs were also TROP2þ , these cells clearly
showed lower TROP2 expression levels compared with LCs.
Furthermore, these cells lacked EpCAM. Similarly, moLCs
generated in the presence of GM-CSF plus IL-4 and TGF-b1
were TROP2þEpCAM. Therefore, among DC subsets,
EpCAM might be a more specific marker for LCs than TROP2.
A key finding of our study is that all dermal CD207þ
DCs co-expressed EpCAM and TROP2. The lack of
CD207þEpCAM cells in human dermis, therefore, implies
that human equivalents to murine dermal CD207þ DCs
(previously identified as CD207þEpCAM dermal cells) do
not exist. In this context, it is interesting that cells with this
phenotype (CD207þEpCAMTROP2) could readily be
detected in lung. Our data therefore indicate that CD207þ
stainings in skin identify epidermal LCs, whereas CD207þ
lung DCs phenotypically differed from LCs in that these cells
lacked EpCAM and TROP2. This study is to our knowledge
the first to demonstrate that human pulmonary and epidermal
CD207þ cells show distinct phenotypic characteristics.
These cells might represent human equivalents of murine
CD103þCD11bCD207þ pulmonary DCs (Sung et al., 2006),
a possibility that might be tested using gene array profiling.
TROP2 mRNA is strongly induced within 24 hours during
TGF-b1-dependent LC lineage commitment of myeloid
progenitor cells. Accordingly, the addition of TGF-b1 to
GM-CSF/IL-4-supplemented monocyte-derived DC cultures
resulted in the induction of TROP2 along with the acquisition
of other LC markers. TROP2 induction was associated with
TGF-b1-dependent progenitor cell commitment to LCs and
was not generally induced upon TGF-b1 stimulation of
progenitors; e.g., TGF-b1 promoted erythroid progenitor cell
differentiation, however, this effect was not accompanied by
TROP2 expression. Therefore, TROP2 is a marker molecule
for TGF-b1-dependent LCs. Future detailed studies
should address the molecular mechanisms underlying
TGF-b1-dependent TROP2 induction concomitant with LC
differentiation.
We demonstrated that CD34þ cell-derived TGF-b1-
dependent CD207þ cells are EpCAMþTROP2þ ; from these
characteristics they resembled epidermal LCs. We previously
demonstrated numerous cytoplasmic Birbeck granules in
these cells, indistinguishable from ex vivo isolated LCs (Strobl
et al., 1996). Together, these findings support that these
in vitro-generated DCs can be used as model cells for LCs. As
mentioned above, moLCs expressed TROP2 but lacked
EpCAM. Therefore, these moLCs lack certain hallmark
features of LCs.
Our data on LC-associated TROP2 expression are compa-
tible with previous observations that TGF-b1 is essential for
the development of LCs (Strobl et al., 1996; Borkowski et al.,
1996a; Kel et al., 2010), whereas it is dispensable for the
development of dermal DCs (Nagao et al., 2009a; Kel et al.,
2010). Therefore, a bright TROP2 expression by LCs might be
indicative for the requirement of LCs on constitutive-active
TGF-b1 signaling. A positive relationship of TROP2 expression
and TGF-b1 signaling may also exist for epithelial cells,
as TROP2 allowed the selection of epithelial stem cells
(Goldstein et al., 2008) and TGF-b1 stimulated sphere
formation of epithelial stem cell (Wang et al., 2011).
It will be interesting to further study the small subset of
murine TROP2þ LCs. These cells might be enriched in
proliferating LCs, in analogy to proliferating hepatic progeni-
tors (Okabe et al., 2009). Alternatively, TROP2þ LCs might
anatomically differ from TROP2 LCs. Interestingly, human
epidermis is a multilayered tissue, with LCs residing in basal/
suprabasal layers, whereas murine epidermis contains only a
few layers. Furthermore, TROP2 expression is diminished in
basal KC layers (Klein et al., 1987), therefore showing a
similar expression pattern as reported for TGF-b1 (Schuster
et al., 2009).
Finally, the question of the functional role of TROP2 and
EpCAM in LC biology remains to be answered. EpCAM and
TROP2 show non-redundant function in human as revealed
by the genetic disorders gelantinous drop like conreal
dystrophy, caused by TROP2 mutations (Tsujikawa et al.,
1999), and tufting enteropathy and Lynch syndrome, caused
by EpCAM mutations (Sivagnanam et al., 2008; Kempers
et al., 2011). Functional data in cancer cell lines indicate a
pro-proliferative role for both molecules (Wang et al., 2008;
Cubas et al., 2010). TROP2 may share downstream effector
pathways with EpCAM; however, unlike EpCAM, the
intracellular domain of TROP2 contains a conserved PIP2
binding domain (El Sewedy et al., 1998). The intracellular tail
of EpCAM translocates to the nucleus to activate b-catenin
signaling (Maetzel et al., 2009), and EpCAM overexpression
counter regulates E-cadherin adhesion (Winter et al., 2003).
As E-cadherin and b-catenin have been implicated in tolero-
genic DC functions (Jiang et al., 2007), it will be interesting
to further study TROP2 and/or EpCAM function in ex
vivo-generated LCs. Because a full knockout of EpCAM in
mice is embryonically lethal (Nagao et al., 2009b), DC-specific
knockout models will be essential for in vivo studies.
With potential clinical applications of our study in mind, it
is noteworthy that TROP2 expression was not detectable in
bone marrow or peripheral blood. Together with the reported
strong overexpression of TROP2 on metastatic tumor cells,
studies should include anti-TROP2 stainings to detect and
quantify circulating tumor cells; this strategy currently mostly
relies on anti-EpCAM stainings (Criscitiello et al., 2010).
MATERIALS AND METHODS
Cells and tissues
CD34þ hematopoietic progenitor cells and CD14þ monocytes
were isolated from cord blood as described (Taschner et al., 2007).
Human and mouse epidermis and dermis were separated following
overnight incubation on Dispase II (1.2Uml1; Roche, Vienna,
Austria) and incubated for 1 hour at 37 1C in phosphate-buffered
saline containing DNAse I (200 mgml1, Sigma-Aldrich, Vienna,
Austria) and trypsin (2mgml1, Sigma-Aldrich) for epidermis or
collagenase IV (4,000Uml1, Sigma-Aldrich) for dermis. Single-cell
suspensions were prepared by filtering the digested tissues through a
70-mm cell strainer (BD Biosciences, Schwechat, Austria). Single-cell
suspensions of lung and intestinal tissue were prepared as described
(Sauer et al., 2006; Ng et al., 2010). Lung and colon specimens were
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obtained from individuals undergoing surgery for tumor removal.
Samples were taken from unaffected tissue at the resection margin.
All procedures were carried out in accordance to the guidelines from
the Medical University of Vienna Institutional Review Board for
these studies. Informed consent was provided in accordance with the
Declaration of Helsinki Principles.
Cytokines and reagents
Human stem cell factor, thrombopoietin, tumor necrosis factor-a),
GM-CSF, fms-related tyrosine kinase 3 ligand (FL), IL-1b, IL-3, and
IL-4 were purchased from PeproTech (London, UK); TGF-b1 was
purchased from R&D Systems (Wiesbaden, Germany); erythropoie-
tin was purchased from Jannsen-Cilag (Vienna, Austria).
In vitro cell culture
CD34þ cord blood cells were cultured serum-free for 2–3 days
under progenitor expansion conditions (fms-related tyrosine kinase 3
ligand, stem cell factor, and thrombopoietin, each at 50 ngml1)
before subculturing with lineage-specific cytokines. LC cultures
were described before (Strobl et al., 1997). For some experiments,
LC clusters were purified as described before (Gatti et al., 2000) and
then further cultured in the presence of GM-CSF (100 ngml1),
tumor necrosis factor-a (25 ngml1), and IL-1b (20 ngml1) to
induce maturation. Erythroblast cultures and CD14þ monocyte-
derived DC, and moLC cultures were described before (Geissmann
et al., 1998; Zermati et al., 2000).
Real-time PCR
Real-time PCR analysis was performed as previously described
(Platzer et al., 2009). The following primers were used: HPRT,
forward 50-GACCAGTCAACAGGGGACAT-30, reverse 50-AACACT
TCGTGGGGTCCTTTTC-30; EpCAM, forward 50-TGCTCTGAGCGA
GTGAGAA-30, reverse 50-TGCAGTCCGCAAACTTTTA-30, and TR
OP2, forward 50-ACAACGATGGCCTCTACGAC-30, reverse 50-AGTT
CACGCACCAGCACAC-30.
Flow cytometry
Flow cytometry staining and analysis was performed as described
(Platzer et al., 2004). Mouse anti-human mAbs, specific for EpCAM
(Alexa-Fluor 488-conjugated), CD324 (APC-conjugated), CD1a, and
glycophorin A (Pacific Blue-conjugated), as well as rat anti-mouse
mAbs specific for major histocompatibility complex-II (phycoerythrin
(PE)-conjugated) and CD45 (APC/Cy7-conjugated) were purchased
from Biolegend (Uithoorn, The Netherlands); mAbs specific for
CD86 (PE-conjugated), HLA-DR (biotinylated), and CD83 (APC-
conjugated), as well as streptavidin-PE/Cy7 were purchased from BD
Biosciences; mAb specific for CD207 (PE-conjugated) was purchased
from Immunotech (Marseille, France); mAb specific for CD45 (APC-
conjugated) was purchased from E-Bioscience (Vienna, Austria);
uncoupled mAb specific for CD71 (clone VIP1) was kindly provided
by O. Majdic, Vienna, Austria; second step reagent was a polyclonal
PE-conjugated goat anti-mouse antibody (Dako, Glostrup, Denmark);
TROP2 was detected using a goat anti-human or anti-mouse
uncoupled polyclonal antibody (R&D Systems); second step reagent
was a polyclonal donkey anti-goat Alexa-Fluor 488-conjugated
antibody (Invitrogen, Lofer, Austria). Cells were routinely stained
with 7-aminoactinomycin D (Sigma-Aldrich) before analysis to
exclude dead cells. Flow cytometric analysis was performed using
an LSRII instrument (BD Biosciences) and the FlowJo software (Tree
Star, Ashland, OR).
Immunohistology
Tissue specimens were stained as described (Go¨bel et al., 2009). For
detection of the TROP2 antibody, slides were probed with a
polyclonal donkey-anti-goat Alexa-Fluor-488-conjugated antibody
(Invitrogen). Nuclei were stained with DAPI and slides were
mounted using fluorescent mounting medium (Dako). Pictures
were taken using an Eclipse 80i microscope (Nikon, Amstelveen,
The Netherlands) and Lucia G software (Laboratory Imaging, Prague,
Czech Republic). Murine epidermal ear sheets were prepared as
described (Nagao et al., 2009a).
Statistical analysis
Statistical analysis was performed using the two-tailed Student’s
t-test; P-values of less than 0.05 were considered significant.
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